NASDAQ$RPRX
Royalty Pharma PLC · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for Q4 and full year 2021, and introduced 2022 Adjusted Cash Receipts guidance.
Royalty Pharma reported strong Q4 and full year 2021 results, with Adjusted Cash Receipts growing by 12% in Q4 and 18% for the full year. The company also announced transactions of $3.0 billion in 2021 and introduced 2022 Adjusted Cash Receipts guidance of $2,225 to $2,300 million.
- Net cash provided by operating activities (GAAP) was $490 million.
- Adjusted Cash Receipts (non-GAAP) reached $543 million.
- Adjusted Cash Flow (non-GAAP) was $488 million.
- Announced transactions of up to $3.0 billion in 2021, including $2.3 billion in upfront payments.
Headline financials
Revenue & EPS history
Royalty Pharma · Revenue · Quarterly
$576M
Revenue by segment
Royalty Pharma · $564M total across 11 segments · Q4 2021
- Cystic Fibrosis Franchise$196M+23.3%34.8%
- Tysabri$94M+1.1%16.7%
- Imbruvica$89M+4.7%15.8%
- Promacta$49M+16.7%8.7%
- Other Products$49M+6.5%8.7%
- Xtandi$41M+5.1%7.3%
- Tremfya$19M—3.4%
- Cabometyx/Cometriq$12M—2.1%
- Evrysdi$6M—1.1%
- Trodelvy$5M+150.0%0.9%
- Erleada$4M+33.3%0.7%
Forward guidance
Royalty Pharma expects 2022 Adjusted Cash Receipts to be between $2,225 million and $2,300 million, excluding new transactions announced after the date of this release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.6%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+6.8%
Q3 2025
Best reaction
-8.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +2.4% | +10.7% | |
| Q4 2025 | +0.1% | +2.2% | +3.3% | |
| Q3 2025 | +6.8% | +1.8% | +5.0% | |
| Q1 2025 | +0.9% | +0.2% | +3.1% | |
| Q4 2024 | +1.7% | +2.0% | +3.0% | |
| Q3 2024 | -3.7% | -4.3% | -5.9% | |
| Q2 2024 | -3.6% | -1.4% | +5.3% | |
| Q1 2024 | +0.4% | +0.3% | -1.9% | |
| Q4 2023 | +2.1% | +3.4% | +2.7% | |
| Q3 2023 | -0.5% | -1.6% | +3.7% | |
| Q2 2023 | -0.9% | -1.1% | -6.4% | |
| Q1 2023 | -4.7% | -2.7% | -2.8% | |
| Q4 2022 | -2.0% | -0.4% | -8.8% | |
| Q3 2022 | +1.6% | +3.7% | -0.1% | |
| Q2 2022 | -0.9% | +1.9% | -1.8% | |
| Q1 2022 | -8.1% | -12.8% | -6.2% | |
| Q4 2021 | +3.6% | +0.8% | +1.7% | |
| Q3 2021 | +1.5% | +5.3% | -4.6% | |
| Q2 2021 | +2.7% | +5.0% | +5.6% | |
| Q1 2021 | -2.2% | -1.8% | +12.4% | |
| Q4 2020 | -2.1% | +1.1% | -1.5% | |
| Q3 2020 | -1.6% | +2.8% | +10.3% | |
| Q2 2020 | -3.0% | -4.2% | -5.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro